世界の癌モノクローナル抗体における提携条件と契約：2016年～2023年

当レポートでは、世界の癌モノクローナル抗体における提携条件と契約について調査し、取引動向と戦略、取引条件、取引タイプ別、治療領域別提携動向などをまとめています。

目次

エグゼクティブサマリー

第1章 イントロダクション

第2章 癌モノクローナル抗体の取引動向

• イントロダクション
• 長年にわたる癌モノクローナル抗体の提携
• 最も活躍する癌モノクローナル抗体の取引業者
• 癌モノクローナル抗体提携、取引タイプ別
• 癌モノクローナル抗体提携、治療領域別
• 癌モノクローナル抗体提携の取引条件

第3章 主要な癌モノクローナル抗体取引

第4章 最も活躍する癌モノクローナル抗体の取引業者

• イントロダクション
• 最も活躍する癌モノクローナル抗体の取引業者
• 最も活躍する癌モノクローナル抗体の提携業者の企業プロファイル

第5章 癌モノクローナル抗体の取引契約ディレクトリ

第6章 癌モノクローナル抗体取引、技術タイプ別

• モノクローナル抗体
• キメラmAb
• ヒト化mAb
• ヒトモノクローナル抗体
• マウスモノクローナル抗体

付録

Wildwood Venturesについて

Description

Cancer Monoclonal Antibody Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the cancer monoclonal antibody deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of cancer monoclonal antibody deals from 2016 to 2023.

The report provides a detailed understanding and analysis of how and why companies enter cancer monoclonal antibody deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 569 cancer monoclonal antibody deals announced since 2016 including financial terms where available including links to online deal records of actual cancer monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of cancer monoclonal antibody dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in cancer monoclonal antibody dealmaking since 2016.

Chapter 3 provides an overview of the leading cancer monoclonal antibody deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in cancer monoclonal antibody dealmaking with a brief summary followed by a comprehensive listing of cancer monoclonal antibody deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of cancer monoclonal antibody deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of cancer monoclonal antibody partnering deals signed and announced since Jan 2016. The chapter is organized by specific cancer monoclonal antibody technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in cancer monoclonal antibody deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Cancer Monoclonal Antibody Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse cancer monoclonal antibody collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Cancer Monoclonal Antibody Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of cancer monoclonal antibody trends and structure of deals entered into by leading biopharma companies worldwide.

Cancer Monoclonal Antibody Collaboration and Licensing Deals includes:

• Trends in cancer monoclonal antibody dealmaking in the biopharma industry
• Directory of cancer monoclonal antibody deal records covering pharmaceutical and biotechnology
• The leading cancer monoclonal antibody deals by value
• Most active cancer monoclonal antibody licensing dealmakers
• Cancer Monoclonal Antibody Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Benefits

Cancer Monoclonal Antibody Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse cancer monoclonal antibody collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in cancer monoclonal antibody dealmaking

• 2.1. Introduction
• 2.2. Cancer monoclonal antibody deals over the years
• 2.3. Most active cancer monoclonal antibody dealmakers
• 2.4. Cancer monoclonal antibody deals by deal type
• 2.5. Cancer monoclonal antibody deals by therapy area
• 2.6. Cancer monoclonal antibody deals by industry sector
• 2.7. Deal terms for cancer monoclonal antibody deals
  • 2.7.1 Cancer monoclonal antibody deals headline values
  • 2.7.2 Cancer monoclonal antibody deal upfront payments
  • 2.7.3 Cancer monoclonal antibody deal milestone payments
  • 2.7.4 Cancer monoclonal antibody royalty rates

Chapter 3 - Leading cancer monoclonal antibody deals

• 3.1. Introduction
• 3.2. Top cancer monoclonal antibody deals by value

Chapter 4 - Most active cancer monoclonal antibody dealmakers

• 4.1. Introduction
• 4.2. Most active cancer monoclonal antibody dealmakers
• 4.3. Most active cancer monoclonal antibody deals company profiles

Chapter 5 - Cancer monoclonal antibody contracts dealmaking directory

• 5.1. Introduction
• 5.2. Cancer monoclonal antibody contracts dealmaking directory

Chapter 6 - Cancer monoclonal antibody dealmaking by technology type

• Deal directory
• Deal directory - Cancer monoclonal antibody deals by company A-Z
• Deal directory - Cancer monoclonal antibody deals by deal type
• Deal directory - Cancer monoclonal antibody deals by therapy area
• Deal type definitions
• About Wildwood Ventures
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering
•  

Table of figures

• Figure 1: Cancer monoclonal antibody deals since 2016
• Figure 2: Active cancer monoclonal antibody dealmaking activity - 2016 - 2023
• Figure 3: Cancer monoclonal antibody deals by deal type since 2016
• Figure 4: Cancer monoclonal antibody deals by therapy area since 2016
• Figure 5: Cancer monoclonal antibody deals by industry sector since 2016
• Figure 6: Cancer monoclonal antibody deals with a headline value
• Figure 7: Cancer monoclonal antibody deals with an upfront value
• Figure 8: Cancer monoclonal antibody deals with a milestone value
• Figure 9: Cancer monoclonal antibody deals with a royalty rate value
• Figure 10: Top cancer monoclonal antibody deals by value since 2016
• Figure 11: Most active cancer monoclonal antibody dealmakers 2016 - 2023
• Figure 12: Cancer monoclonal antibody deals by technology type since 2016